医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LFB S.A.宣布,评估重组因子7有效性的PerSept 1前瞻性临床试验达到患者入组目标

2014年12月18日 PM11:26
このエントリーをはてなブックマークに追加
Related Posts Plugin for WordPress, Blogger...
TimeLine:

同じカテゴリーの記事 

  • Advanced Clinical’s Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders
  • Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
  • Fabrinet to Announce Fourth Quarter and Fiscal-Year 2021 Financial Results on August 16, 2021
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration
  • IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials